未折叠的·维勒布兰德因子结合S蛋白,并降低抗凝剂活性
Martha M S Sim1, Molly Y Mollica2,3,4, Hammodah R Alfar1
1Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY.
Blood vessels, thrombosis & hemostasis
|June 16, 2025
概括
病毒感染中血蛋白S (PS) 缺乏是由于与·维勒布兰德因子 (VWF) 的相互作用引起的. 这种结合降低了PS的抗凝活性,增加了感染期间的血栓形成风险.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 血蛋白S (PS) 存在于自由 (抗凝固剂) 和C4BP结合的 (抗炎症) 形式.
- 在病毒感染中观察到获得的自由PS缺乏症,但其潜在机制仍然未知.
研究的目的:
- 为了阐明在病毒感染中自由PS缺乏的原因.
- 为了确定PS和·威尔布兰德因子 (VWF) 之间的相互作用及其功能后果.
主要方法:
- 质谱和交叉连接来检测PS/VWF相互作用.
- 微流体系统研究PS在剪切应力下与展开的VWF结合.
- 血栓生成试验用于评估抗凝剂活性.
主要成果:
- 确定了PS和VWF之间的切削依赖相互作用.
- 聚氨酸结合到VWF的剪切暴露部位,减少自由的PS及其抗凝功能.
- 在COVID-19患者中,自由PS缺乏与VWF水平和血栓生成相关.
结论:
- 在PS和VWF之间的相互作用封存自由PS,降低抗凝活性.
- 这种PS/VWF相互作用可能会导致与病毒感染相关的血栓形成风险.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
932
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
932
Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K
Formation of the Platelet Plug
7.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.2K
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K


